Presents innovation-driven ecological structure of the healthcare trade
MACAO SAR – Media OutReach – 3 December 2021 – From 2 to 4 December, 2021, specializing in know-how innovation and its affect on varied industries to the society, the primary BEYOND Worldwide Know-how Innovation Expo (“BEYOND Expo”) in Macao is held on the Venetian Macao Conference and Exhibition Centre. Specializing in cutting-edge know-how, Fosun Pharma along with its member enterprises within the sectors overlaying pharmaceutical manufacturing, medical units and healthcare providers to hitch the life science exhibition (Sales space No.: B07). Fosun Pharma’s innovation-driven ecological structure in addition to its breakthroughs and developments of the healthcare trade are properly introduced.
Mr. Ho Iat Seng, Chief Government of Macao SAR visited the Fosun Pharma sales space.
Wu Yifang, Chairman and CEO of Fosun Pharma mentioned: “The profitable internet hosting of the BEYOND Expo in Macao demonstrates the Macao Particular Administrative Area Authorities’s confidence within the outcomes of anti-pandemic and its high-level organizational capabilities. Fosun Pharma is glad to take part on this progressive know-how occasion, by bringing a wide range of merchandise within the anti-tumor subject and the show of progressive achievements with worldwide cooperation. Sooner or later, we are going to additional launch our vitality on the healthcare innovation on this area, proceed to optimize the operational effectivity of the healthcare providers enterprise, speed up the development of advantageous disciplines, and promote the high-quality improvement of the healthcare trade within the Better Bay Space. Oriented in the direction of affected person wants, we will even enhance the accessibility of the world’s main medical services and products in China, so that each household may take pleasure in good well being. “
Deeply cultivating the oncology subject, creating plenty of FIRST influential merchandise within the trade
Fosun Pharma is dedicated to selling progressive R&D with its pharmaceutical enterprise as its core, and is oriented in the direction of fulfilling unmet medical wants and enhancing merchandise’ accessibility, accelerating the implementation of progressive applied sciences and merchandise. On the BEYOND Expo, Fosun Pharma presents a wide range of self-developed and co-developed medication within the oncology subject. After over a decade of steady funding, Fosun Pharma has ushered in plenty of merchandise within the anti-tumor subject which were authorized in recent times. On the similar time, Fosun Pharma continues to extend the product accessibility in varied methods to learn extra sufferers.
Because the biopharmaceutical platform of Fosun Pharma, Henlius has all the time been dedicated to providing high-quality progressive biologic medicines for sufferers worldwide with a give attention to oncology, autoimmune ailments and ophthalmic ailments. Henlius brings a wide range of R&D achievements within the anti-tumor subject and its diversified merchandise to the BEYOND Expo, together with three merchandise which were authorized for advertising: the China’s first biosimilar Han Li Kang (Rituximab), the primary self-developed Chinese language mAb biosimilar getting into each the EU and China market Han Qu You (Trastuzumab), the corporate’s first product indicated for the therapy of autoimmune ailments Han Da Yuan (Adalimumab).
On the similar time, Henlius additionally brings the novel anti-PD-1 mAb Serplulimab independently developed by the corporate which has been authorized for medical trials in China, america, the European Union and different nations and areas. The indications cowl a variety of tumor varieties with excessive incidence reminiscent of lung most cancers, esophageal most cancers, hepatocellular most cancers, gastric most cancers and head and neck most cancers, with round 2,300 sufferers have been enrolled globally. The NDA for the therapy of microsatellite instability-high (MSI-H) stable tumors has been accepted by the Nationwide Medical Merchandise Administration (NMPA) and proposed to be granted precedence evaluation in April 2021. It’s anticipated to be authorized for advertising within the first half of 2022. Moreover, the NDA submitting of the first-line therapy of squamous non-small cell lung most cancers (sqNSCLC) has been accepted by NMPA in September 2021.
In June 2021, the primary CAR-T cell remedy Yi Kai Da (Axicabtagene Ciloleucel) of Fosun Kite, a three way partnership, has been authorized for advertising by NMPA, which was China’s first CAR-T remedy authorized for the therapy of grownup sufferers with relapsed or refractory massive B-cell lymphoma, opening a brand new period of cell remedy in China. After its launch, the drug has achieved sure breakthroughs in affected person entry and medical advantages, CAR-T tutorial communications, and exploration of recent indications within the commercialization stage of the drug in China. When it comes to cost innovation, the drug has been included in business insurances and customised insurances in lots of cities.
Deploy cutting-edge mRNA vaccine, responding to variations of the virus actively
On the BEYOND Expo, Fosun Pharma presents the COVID-19 mRNA vaccine BNT162b2, which was collectively developed with BioNTech. It has been referred to as the primary COVID-19 mRNA vaccine authorized by U.S. Meals and Drug Administration (FDA), and expanded the emergency use authorization of a booster dose to incorporate people 18 years of age and older. COVID-19 mRNA vaccine BNT162b2 has been included within the authorities vaccination packages in Hong Kong SAR and Macao SAR. As of 27 November 2021, greater than 13.5 million doses of COVID-19 mRNA vaccine BNT162b2 have been administered in Hong Kong, Macao and Taiwan. Amongst them, greater than 69,000 individuals in Hong Kong SAR and Macao SAR have obtained the third dose of COVID-19 mRNA vaccine BNT162b2.
The COVID-19 pandemic remains to be spreading globally. The Omicron variant poses new challenges to the prevention and management. Fosun Pharma actively promotes tutorial communications on public well being within the Better Bay Space. Earlier, on the “Guangdong-Hong Kong-Macao Better Bay Space Public Well being Know-how Innovation Work Seminar” hosted by the Guangdong Preventive Drugs Affiliation and arranged by Fosun Pharma, plenty of public well being consultants and students from the Guangdong-Hong Kong-Macao Better Bay Space shared their views on the COVID-19 pandemic prevention and management methods. Amongst them, consultants and students from Hong Kong shared their expertise in pandemic prevention, management and COVID-19 therapy. When it comes to immunization methods, Hong Kong has authorized the third dose of COVID-19 vaccine for the high-risk populations.
Proceed to deepen the structure of healthcare providers within the Better Bay Space, serving to to realize Wholesome China 2030
In accordance with the deployment of the “‘Wholesome China 2030’ blueprint“: By 2030, the institutional system for selling well being for all might be improved, the event of the well being subject might be extra coordinated, wholesome life might be popularized, and the standard of well being providers and well being safety will proceed to enhance.” The Guangdong-Hong Kong-Macao Better Bay Space is among the most open and economically dynamic areas in China, and performs a strategic position in nationwide improvement.
Beneath the steering of the nationwide methods of Wholesome China 2030 and Innovation Pushed, Fosun Well being has gone by means of a few years of intensive industrial cultivation, it has owned and operated many for-profit common hospitals with benefits in model and medical capabilities in Better Bay Space, reminiscent of Foshan Fosun Chancheng Hospital (known as “Foshan Chancheng Hospital”), Shenzhen Heng Sheng Hospital, Zhuhai Chancheng Hospital and Guangzhou Xinshi Hospital. Whereas deepening the structure, Fosun Well being integrates some great benefits of its member hospitals, focuses on constructing a world high quality and security system, strengthens the development of disciplines and specialist alliances, strengthens technological innovation and high-level medical know-how innovation, and consolidates onerous power.
In the meantime, Fosun Well being actively promotes the rational allocation and optimization of medical sources such because the physician group. In expertise coaching, by means of the Nice Well being Administration Faculty, Fosun Well being may practice progressive administration abilities for the Better Bay Space and even for the home healthcare trade. Within the period of digital transformation, whereas strengthening the development of good hospitals within the Better Bay Space, Fosun Well being additionally makes use of on-line and offline medical to advertise company cloud medical workplace providers and obtain full protection of 500 corporations within the Better Bay Space.
Foshan Chancheng Hospital, the flagship Hospital of Fosun Well being, additionally participated within the BEYOND Expo. As a 3A hospital rating No. 1 within the China Non-Public Hospital Complete Competitiveness and authorized by the Joint Fee Worldwide (JCI) Accreditation Requirements for Hospitals, Foshan Chancheng Hospital, headed by its “Three Treasures of Chancheng Hospital” (intervertebral disc, stone elimination, and start), has arrange a collection of specialties reminiscent of the guts middle, the mind middle, and the “Zen” anti-aging medication middle to appreciate know-how and repair twin wheel drive.
As well as, within the subject of medical units, Fosun Pharma has systematically deployed three main enterprise divisions with medical cosmetology, respiratory care, {and professional} medical care. Adhering to the client because the core and to the worldwide shopper wellness eco-system technique, and persevering with to strengthen the development of the worldwide advertising system, Fosun Pharma actively promotes the touchdown of plenty of world-leading medical applied sciences and cutting-edge medical tools in China.
On the BEYOND Expo, Sisram Medical, the worldwide main supplier of energy-based surgical and medical aesthetics options, and Breas, the well-known European ventilator model, in addition to the ultra-light and ultra-small CPAP moveable ventilator Z1 Auto, are properly introduced.
On the similar time, as a locally-incubated medical synthetic intelligence firm, Fosun Aitrox additionally brings its medical, digital and clever built-in resolution, which makes use of huge information and deep studying to construct breakthrough clever purposes to realize the mixing of synthetic intelligence in a number of medical departments. The collaborative utility from totally different medical departments may enhance the effectivity, and actually notice AI-driven medical know-how providers.
About Fosun Pharma
Based in 1994, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”; inventory code: 600196.SH, 02196.HK) is a number one innovation-driven worldwide healthcare group in China. Fosun Pharma strategically operates companies within the pharmaceutical and well being trade, together with pharmaceutical manufacturing, medical units and medical analysis, and healthcare providers. By fairness participation in Sinopharm Co., Ltd., Fosun Pharma’s enterprise extends to pharmaceutical distribution and retail.
Fosun Pharma takes pharmaceutical manufacturing as its core enterprise and sticks to progressive analysis and improvement. By in-house R&D, co-development, in-licensing and incubation, Fosun Pharma had established platforms for small molecule progressive medication, antibody medication and cell remedy, specializing in main therapeutic areas, together with oncology, immunology, “4 hypers” (hypertension, hyperlipidemia, hyperglycemia and hyperuricemia) and their issues, in addition to central nervous system. Within the meantime, Fosun Pharma retains shut monitor of cutting-edge applied sciences, reminiscent of focused protein degradation, RNA, oncolytic virus and gene remedy to reinforce its innovation capability.
Wanting ahead, underneath steering of 4IN technique (Innovation, Internationalization, Integration and Intelligentization), Fosun Pharma practices innovation and transformation, built-in operation and regular improvement, in addition to the idea of sustainable improvement. Fosun Pharma is dedicated to turning into the first-class enterprise within the international mainstream healthcare trade.
For extra data, please go to: 
www.fosunpharma.com.
#FosunPharma
Fosun Pharma Ahead-looking statements:
This press launch incorporates forward-looking statements. All statements different than statements of historic reality contained in this press launch, together with, with out limitation, the discussions of the Firm’s enterprise methods and expectations regarding future operations, margins, profitability, liquidity and capital sources, the future improvement of the Firm’s trade and the future improvement of the common financial system of the Firm’s key markets and any statements preceded by, adopted by or that embrace phrases and expressions such as “count on”, “search”, “imagine”, “plan”, “intend”, “estimate”, “undertaking”, “anticipate”, “could”, “will”, “would” and “may” or related phrases or statements, as they relate to the Firm or its administration, are meant to establish forward-looking statements. These statements are topic to sure identified and unknown dangers, uncertainties and assumptions, which could trigger the Firm’s precise outcomes, efficiency or achievements to be materially totally different from any future outcomes, efficiency or achievements expressed or implied by these forward-looking statements. Accordingly, you ought to not place undue reliance on any forward-looking data. Topic to the necessities of relevant legal guidelines, guidelines and rules, the Firm does not have any and undertakes no obligation to replace or in any other case revise the forward- wanting statements in this press launch, whether or not as a results of new data, future occasions or developments or in any other case. On this press launch, statements of or references to the Firm’s intentions are made as of the date of this press launch. Any such intentions could change in gentle of future developments. All forward-looking statements contained on this press launch are certified by reference to the cautionary statements set out above.
